|
Report Date : |
23.08.2013 |
IDENTIFICATION DETAILS
|
Name : |
DELTA PHARMA BIO CO SAE |
|
|
|
|
Registered Office : |
Villa 274 El Shawayfat Street Al Tajamou Al Khamesh Cairo |
|
|
|
|
Country : |
Egypt |
|
|
|
|
Date of Incorporation : |
01.01.2010 |
|
|
|
|
Com. Reg. No.: |
3413, Cairo |
|
|
|
|
Legal Form : |
Closed Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacturer of pharmaceuticals. |
|
|
|
|
No. of Employees : |
100 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Egypt |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
EGYPT - ECONOMIC OVERVIEW
Occupying the northeast corner of the African continent, Egypt
is bisected by the highly fertile Nile valley, where most economic activity
takes place. Egypt's economy was highly centralized during the rule of former
President Gamal Abdel NASSER but opened up considerably under former Presidents
Anwar EL-SADAT and Mohamed Hosni MUBARAK. Cairo from 2004 to 2008 aggressively
pursued economic reforms to attract foreign investment and facilitate GDP
growth. Despite the relatively high levels of economic growth in recent years,
living conditions for the average Egyptian remained poor and contributed to
public discontent. After unrest erupted in January 2011, the Egyptian
Government backtracked on economic reforms, drastically increasing social
spending to address public dissatisfaction, but political uncertainty at the
same time caused economic growth to slow significantly, reducing the
government's revenues. Tourism, manufacturing, and construction were among the
hardest hit sectors of the Egyptian economy, and economic growth is likely to
remain slow during the next several years. The government drew down foreign
exchange reserves by more than 50% in 2011 and 2012 to support the Egyptian
pound and the dearth of foreign financial assistance - as a result of
unsuccessful negotiations with the International Monetary Fund over a
multi-billion dollar loan agreement which have dragged on more than 20 months -
could precipitate fiscal and balance of payments crises in 2013.
Source
: CIA
Company Name : DELTA PHARMA BIO CO SAE
Country of Origin : Egypt
Legal Form : Closed Joint Stock Company
Registration Date : 1st January 2010
Commercial Registration Number : 3413, Cairo
Issued Capital : £E 50,000,000
Paid up Capital : £E 50,000,000
Total Workforce : 100
Activities : Manufacturer of pharmaceuticals.
Financial Condition : Undetermined
Payments : Nothing detrimental uncovered
Person Interviewed : Yehia Abo Zahra, Administration Manager
DELTA PHARMA BIO CO SAE
Building : Villa 274
Street : El Shawayfat
Street
Area : Al Tajamou
Al Khamesh
Town : Cairo
Country : Egypt
Telephone : (20-2) 26160342
/ 29294994
Facsimile : (20-2)
26160343
Mobile : (20-111)
5011111 / (20-114) 4405950
Email : info@deltapharmabio.com / mh@detlapharmabio.com / y_abozahra@deltapharmabio.com
Subject operates from a medium sized suite of offices that are rented
and located in the Central Business Area of Cairo.
Name Position
· Dr Mohy Mohamed
Hafiz Managing
Director
· Hanan Mohamed Hafiz Director
· Somaya Mohamed Fouad Ismail Director
· Dr Ashraf El Sayed Export
Manager
· Sayed Nafie Financial
Manager
· Yehia Abo Zahra Administration
Manager
Date of
Establishment : 1st
January 2010
Legal Form : Closed Joint Stock Company
Commercial Reg. No. : 3413, Cairo
Issued Capital : £E 50,000,000
Paid up Capital : £E 50,000,000
· Dr Mohy Mohamed
Hafiz
· Hanan Mohamed Hafiz
· Somaya Mohamed Fouad Ismail
Activities: Engaged in the manufacture of pharmaceuticals, food supplements,
cosmetics, antibiotics and animal
health products.
Import Countries: Europe and the Far East.
Subject has a workforce of 100 employees.
Companies registered in Egypt are not legally required to make their
accounts public and no financial information was released by the company or
submitted by outside sources.
·
Citibank
PO Box: 188
Cairo
Tel: (20-2)
23551877 / 23551874
Fax: (20-2)
23558056
No complaints regarding subject’s payments have been reported.
During the course of this investigation nothing detrimental was
uncovered regarding subject’s operating history or the manner in which payments
are fulfilled. As such the company is considered to be a fair trade risk.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.42 |
|
|
1 |
Rs.102.09 |
|
Euro |
1 |
Rs.87.32 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.